Invivyd, Inc. (NASDAQ:IVVD) Given Average Recommendation of “Hold” by Brokerages

Invivyd, Inc. (NASDAQ:IVVD) has received a consensus rating of “Hold” from the six ratings firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $8.00.

A number of brokerages have weighed in on IVVD. HC Wainwright raised their target price on Invivyd from $5.00 to $10.00 and gave the company a “buy” rating in a report on Friday, October 31st. D. Boral Capital restated a “hold” rating on shares of Invivyd in a research report on Tuesday, November 25th. BTIG Research reaffirmed a “buy” rating on shares of Invivyd in a research note on Wednesday, January 21st. Zacks Research upgraded Invivyd from a “strong sell” rating to a “hold” rating in a research report on Thursday, November 13th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Invivyd in a research note on Monday, December 29th.

Insider Transactions at Invivyd

In other news, Director Kevin F. Mclaughlin bought 50,000 shares of the stock in a transaction on Wednesday, November 19th. The stock was acquired at an average price of $2.50 per share, with a total value of $125,000.00. Following the acquisition, the director directly owned 50,000 shares in the company, valued at approximately $125,000. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 25.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Invivyd

A number of institutional investors have recently modified their holdings of the company. Hudson Bay Capital Management LP acquired a new stake in Invivyd during the 4th quarter worth about $215,000. Rafferty Asset Management LLC bought a new stake in shares of Invivyd during the 4th quarter valued at about $703,000. Charles Schwab Investment Management Inc. bought a new stake in shares of Invivyd during the 4th quarter valued at about $291,000. Siren L.L.C. acquired a new stake in Invivyd during the fourth quarter worth approximately $9,880,000. Finally, State Street Corp increased its holdings in Invivyd by 1,636.7% in the fourth quarter. State Street Corp now owns 5,637,593 shares of the company’s stock worth $13,925,000 after purchasing an additional 5,312,986 shares in the last quarter. 70.36% of the stock is owned by institutional investors.

Invivyd Trading Up 2.0%

NASDAQ IVVD opened at $1.56 on Monday. The firm’s 50 day simple moving average is $2.24 and its 200 day simple moving average is $1.73. The firm has a market capitalization of $363.67 million, a price-to-earnings ratio of -3.32 and a beta of 0.60. Invivyd has a 1 year low of $0.46 and a 1 year high of $3.07.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.